中国全科医学2013，Vol.16Issue(18)：2067-2070,4.DOI:10.3969/j.issn.1007-9572.2013.06.079
微生态制剂辅助治疗幽门螺杆菌感染的研究进展
Development of Probiotics Adjuvant Therapy on Infection of Helicobacter Pylori
吕志发 1谢勇1
作者信息
- 1. 330006,江西省南昌市,南昌大学第一附属医院
- 折叠
摘要
Abstract
Helicobacter pylori are closely associated with various gastrointestinal diseases, such as peptic ulcer, chronic gastritis, gastric mucosal - associated lymphatic tissue lymphoma and gastric cancer. Recently, with triple therapy and other eradication regimens being widely used, the Helicobacter pylori resistance rates to antibiotics are getting higher, and the eradication efficacy is decreasing. Probiotics can inhibit the growth of Helicobacter pylori through binding the site in epithelial cells and restraining inflammation reaction induced by Helicobacter pylori, and it can improve the immune ability and barrier of mucosa, and can produce some substances that can inhibit Helicobacter pylori. Probiotics can also decrease the side effects of eradication regimens. Therefore, it can be safely used to adjuvant therapy for eradicating Helicobacter pylori.关键词
螺杆菌,幽门/微生态制剂/消化性溃疡/胃炎Key words
Helicobacter pylori/ Probiotics/ Peptic ulcer/ Gastritis分类
医药卫生引用本文复制引用
吕志发,谢勇..微生态制剂辅助治疗幽门螺杆菌感染的研究进展[J].中国全科医学,2013,16(18):2067-2070,4.
